EXPERIMENTAL HEMATOLOGY
Scope & Guideline
Pioneering Insights into Blood Disorders and Their Treatments
Introduction
Aims and Scopes
- Hematopoiesis and Stem Cell Biology:
The journal covers extensive research on the mechanisms of hematopoiesis, including the development, differentiation, and function of hematopoietic stem cells (HSCs), progenitor cells, and their niches. - Hematological Malignancies:
Research on the molecular and cellular basis of hematological cancers, including leukemias, lymphomas, and myeloproliferative neoplasms, is a core area of focus, particularly mechanisms of tumorigenesis and therapeutic resistance. - Therapeutic Innovations:
EXPERIMENTAL HEMATOLOGY publishes studies on novel therapeutic strategies, including gene therapy, immunotherapy, and targeted treatments for hematological diseases, highlighting translational research. - Microenvironment and Niche Interactions:
The journal emphasizes the role of the bone marrow microenvironment and other niches in regulating hematopoietic cell behavior, interactions between different cell types, and their impact on disease. - Epigenetics and Transcriptional Regulation:
Research exploring the epigenetic landscape and transcriptional control mechanisms governing hematopoietic development and malignancies is prominently featured, reflecting the journal's commitment to understanding gene regulation. - Systemic and Local Regulation of Hematopoiesis:
Studies addressing the systemic factors influencing hematopoiesis and the local signals from the microenvironment that modulate hematopoietic function are integral to the journal's scope.
Trending and Emerging
- Single-Cell Technologies:
An increasing number of studies are employing single-cell RNA sequencing and other single-cell technologies to elucidate the heterogeneity of hematopoietic stem and progenitor cells, providing insights into their function and regulation. - Metabolic Regulation:
Research focusing on the metabolic pathways that influence hematopoietic stem cell function and differentiation is gaining prominence, highlighting the interplay between metabolism and cell fate. - Inflammation and Immune Interactions:
The role of inflammation and immune responses in regulating hematopoiesis and hematological malignancies is an emerging theme, with studies investigating how these factors influence disease progression. - Gene Editing and Genetic Models:
There is a notable increase in studies utilizing advanced gene editing techniques (e.g., CRISPR/Cas9) to model hematological diseases and explore genetic factors contributing to malignancies. - Epitranscriptomics:
The exploration of RNA modifications (e.g., m6A methylation) and their impact on gene expression and hematopoietic function is an emerging area of interest, reflecting the evolving understanding of post-transcriptional regulation. - Therapeutic Targeting of the Microenvironment:
Research targeting the bone marrow microenvironment to enhance hematopoietic stem cell recovery and improve treatment outcomes in hematological malignancies is gaining traction, indicating a shift towards niche-focused therapies.
Declining or Waning
- Traditional Animal Models:
Research utilizing conventional animal models for hematopoiesis and leukemia studies is less frequently published, potentially due to the increasing adoption of advanced in vitro and humanized models. - Basic Hematology without Translational Focus:
Papers focusing solely on basic hematological research without clear translational implications are becoming less common, as the field increasingly emphasizes studies that bridge basic science with clinical application. - Single-Agent Therapeutic Studies:
The publication of studies focusing exclusively on single-agent therapies without exploring combination strategies or innovative approaches appears to be declining, reflecting a shift towards more complex treatment paradigms. - Epidemiological Studies:
There has been a noticeable decrease in the publication of epidemiological studies related to hematological disorders, possibly due to a growing emphasis on mechanistic and experimental research.
Similar Journals
CELL PROLIFERATION
Bridging Knowledge Gaps in Cell Proliferation StudiesCELL PROLIFERATION, published by Wiley, is a leading open-access journal that has been at the forefront of research since its inception in 1968. With an impact factor that solidifies its position in the Q1 category of both Cell Biology and Medicine (Miscellaneous), this journal serves as a premier platform for disseminating groundbreaking studies in the field of cellular and molecular biology. The journal is renowned for its rigorous peer-review process and comprehensive coverage of topics related to cell growth, division, and differentiation, making it an invaluable resource for researchers, professionals, and students alike. With its notable Scopus ranking of #30 in Biochemistry, Genetics, and Molecular Biology: Cell Biology, and a robust open access model since 2019, CELL PROLIFERATION ensures that cutting-edge research is accessible to a global audience, fostering collaboration and innovation across the scientific community. Located in the United Kingdom, the journal remains committed to enhancing the understanding of cellular processes, thereby influencing developments in medicine and biotechnology.
Experimental Hematology & Oncology
Pioneering Insights in Hematology and OncologyExperimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.
CURRENT OPINION IN HEMATOLOGY
Advancing hematological knowledge for better patient care.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
Journal of Hematology & Oncology
Pioneering Discoveries in Hematology and OncologyJournal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.
HEMATOLOGICAL ONCOLOGY
Shaping the Future of Cancer Treatment and ResearchHEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.
Cell Discovery
Advancing the Frontiers of Cellular ScienceCell Discovery, published by SPRINGERNATURE, is a premier open access journal in the dynamic fields of Biochemistry, Cell Biology, Genetics, and Molecular Biology. Since its inception in 2015, this journal has established itself as a key platform for disseminating high-impact research and is recognized with a Q1 ranking across all its core categories for the year 2023. With its remarkable Scopus rankings—7th in Genetics, 9th in Biochemistry, 13th in Molecular Biology, and 15th in Cell Biology—Cell Discovery positions itself among the elite journals in life sciences, showcasing the most innovative breakthroughs and comprehensive reviews. Based in the United Kingdom, this journal operates under an open access model, ensuring that groundbreaking discoveries are readily available to researchers, professionals, and students around the globe. With a commitment to advancing scientific knowledge, Cell Discovery welcomes contributions that push the frontiers of our understanding in cellular and genetic sciences.
STEM CELLS AND DEVELOPMENT
Elevating Knowledge in Stem Cell Biology and DevelopmentSTEM CELLS AND DEVELOPMENT, published by Mary Ann Liebert, Inc., is a leading peer-reviewed journal dedicated to the rapidly advancing fields of stem cell biology and developmental science. With an ISSN of 1547-3287 and an E-ISSN of 1557-8534, the journal encompasses a broad range of topics central to understanding stem cells' roles in development and regeneration processes. It holds a prestigious standing within its category quartiles, ranking Q3 in Cell Biology, Q2 in Developmental Biology, and Q2 in Hematology for 2023. With its convergence from 2004 to 2024, STEM CELLS AND DEVELOPMENT fosters an innovative platform for researchers, professionals, and students to disseminate groundbreaking research, share insights, and explore novel therapeutic approaches. Open access options enhance the journal's visibility and accessibility, promoting a collaborative exchange of information among the scientific community. Positioned at the forefront of stem cell research and its applications, this journal is vital for anyone seeking to stay informed about the latest advancements and trends within these critical areas of study.
Therapeutic Advances in Hematology
Unlocking new horizons in hematological advancements.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.
Blood Science
Navigating the Complexities of Blood HealthBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
CELLULAR & MOLECULAR BIOLOGY LETTERS
Fostering Collaboration in the World of Molecular DiscoveriesCELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.